<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management and prognosis of parapneumonic effusion and empyema in children</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management and prognosis of parapneumonic effusion and empyema in children</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management and prognosis of parapneumonic effusion and empyema in children</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ibrahim A Janahi, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Khoulood Fakhoury, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gregory Redding, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morven S Edwards, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 11, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Parapneumonic effusion is defined as pleural effusion associated with lung infection (ie, pneumonia). These effusions result from the spread of inflammation and infection to the pleura. Much less commonly, infections in other areas adjacent to the pleura, such as the retropharyngeal, vertebral, abdominal, and retroperitoneal spaces, may spread to the pleura, resulting in the development of effusion.</p><p>Early in the course of parapneumonic effusion, the pleura becomes inflamed; subsequent leakage of proteins, fluid, and leukocytes into the pleural space forms the effusion. At the time of formation, the pleural effusion is usually sterile with a low leukocyte count. With time, bacteria invade the fluid, resulting in empyema, which is defined as the presence of grossly purulent fluid in the pleural cavity. The development of pleural empyema is determined by a balance between host resistance, bacterial virulence, and timing of presentation for medical treatment [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/6344.html" rel="external">"Epidemiology, clinical presentation, and evaluation of parapneumonic effusion and empyema in children", section on 'Pathophysiology'</a>.)</p><p>The management of parapneumonic effusion and empyema in children will be reviewed here. The epidemiology, etiology, pathophysiology, clinical presentation, and evaluation of parapneumonic effusion and empyema in children are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6344.html" rel="external">"Epidemiology, clinical presentation, and evaluation of parapneumonic effusion and empyema in children"</a>.)</p><p>The evaluation and management of parapneumonic effusion in adults also are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6698.html" rel="external">"Pleural fluid analysis in adults with a pleural effusion"</a> and  <a class="medical medical_review" href="/z/d/html/6688.html" rel="external">"Imaging of pleural effusions in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6702.html" rel="external">"Epidemiology, clinical presentation, and diagnostic evaluation of parapneumonic effusion and empyema in adults"</a>.)</p><p class="headingAnchor" id="H242606626"><span class="h1">DEFINITIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Parapneumonic effusion</strong> is defined as pleural effusion associated with lung infection (ie, pneumonia). Early in the disease course, the effusion usually is free-flowing (also known as a "simple" effusion) and sterile.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Loculated parapneumonic effusion</strong> refers to the presence of septations (separate compartments) within the effusion, which interfere with free flow of fluid. Loculation usually is detected by imaging (ultrasonography or computed tomography [CT]). Loculation is caused by accumulation of proteinaceous debris in the fluid as the disease progresses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Empyema</strong> is defined as the presence of bacterial organisms on Gram stain and/or grossly purulent fluid in the pleural cavity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complicated parapneumonic effusion</strong> refers to changes in the pleural fluid due to bacterial invasion into the pleural space. Because bacteria are cleared rapidly after antibiotic therapy, cultures of fluid from complicated parapneumonic effusions are often negative. In clinical practice, the term is often used to refer to either loculated effusion or empyema.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complicated pneumonia</strong> refers to pneumonia with any complication, including loculated parapneumonic effusion, empyema, or (more rarely) pneumothorax, necrotizing pneumonia, or lung abscess.</p><p></p><p class="headingAnchor" id="H2"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>Both medical and surgical interventions have a role in the management of parapneumonic effusion in children [<a href="#rid2">2,3</a>]. The goals of therapy include sterilization of the pleural cavity, resolution of pleural fluid, and reexpansion of the lung. Selection of treatment depends upon factors including the patient's respiratory status and the size and loculation of the fluid collection, as well as the response to initial interventions. With appropriate treatment, outcomes are generally excellent.</p><p>Clinical experience and data from studies of parapneumonic effusion in adults cannot be extrapolated to children, because underlying lung disorders are more common in adults and the morbidity and mortality of parapneumonic effusion in adults are higher than in children.</p><p class="headingAnchor" id="H4"><span class="h2">Hospitalization</span><span class="headingEndMark"> — </span>The majority of patients with pneumonia complicated by parapneumonic effusions will require hospitalization. Transfer to a facility with specialists in pediatric pulmonology, pediatric surgery, and pediatric anesthesia should be considered early in the care of children who may require video-assisted thoracoscopic surgery (VATS) or fibrinolytic therapy [<a href="#rid2">2</a>].</p><p>Occasionally, patients with small parapneumonic effusions who are clinically well and are responding to outpatient therapy can be managed without hospitalization, providing that they are followed closely to monitor progress. Indications for hospitalization include ages younger than six months, evidence of bacteremia or respiratory compromise, and failure of outpatient management [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/z/d/html/6054.html" rel="external">"Pneumonia in children: Inpatient treatment", section on 'Hospitalization'</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Clinical course</span><span class="headingEndMark"> — </span>Parapneumonic effusion and empyema is a disease process that evolves over time, and different management strategies are appropriate at different stages [<a href="#rid3">3</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In early stages, children tend to have small effusions and are in no respiratory distress; such patients usually can be managed as outpatients, with broad-spectrum oral antibiotics and close observation with chest radiographs on an outpatient basis. (See <a class="local">'Small parapneumonic effusion'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Later in the evolution of the process, the effusion may become larger and may compromise respiratory function, requiring hospitalization, intravenous (IV) antibiotics, ultrasound assessment, and drainage of pleural effusion [<a href="#rid2">2,5</a>]. (See <a class="local">'Moderate or large simple effusion (not loculated)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Subsequently, the effusion may become loculated or organized, and/or frankly infected (empyema). This stage usually requires more aggressive therapy, including fibrinolytic therapy or surgical debridement/drainage of the pleural space [<a href="#rid6">6</a>]. Expert opinion on the optimal type and timing of drainage and surgical intervention continues to evolve, and management remains somewhat controversial [<a href="#rid2">2</a>]. (See <a class="local">'Loculated effusion or empyema'</a> below.)</p><p></p><p>Children with pneumonia-associated pleural disease can present initially with an effusion that is in any one of these stages of evolution. Management depends on the stage of evolution of the parapneumonic process and what therapy has already been provided. In some cases, oral antibiotics may have already been initiated in the outpatient setting before the effusion became apparent.</p><p class="headingAnchor" id="H242599713"><span class="h1">SUPPORTIVE CARE</span><span class="headingEndMark"> — </span>Supportive care for children with parapneumonic effusion may include antipyretics, analgesia, and early ambulation [<a href="#rid2">2</a>]. Children with empyema are invariably febrile; antipyretics should be used for comfort as needed, with the caveat that their use may mask the resolution of fever, which is one of the indicators of clinical progress. Analgesia should be used to treat pleuritic pain, which may interfere with breathing and affect the child's willingness to cough. Adequate analgesia will also help with early ambulation and other measures to encourage lung expansion. However, analgesia should be tailored to the patient's symptoms rather than regularly scheduled to permit monitoring of clinical improvement. Sedatives may cause central respiratory depression and should be used sparingly and cautiously, with close monitoring of respiratory status.</p><p>Children with parapneumonic effusions may become dehydrated as a result of poor intake and increased losses from fever and tachypnea. IV fluids should be administered if the child refuses oral intake or is unable to drink. However, close attention must be paid to fluid balance since these children also are at risk for developing syndrome of inappropriate antidiuretic hormone secretion (SIADH). (See  <a class="medical medical_review" href="/z/d/html/2384.html" rel="external">"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)"</a>.)</p><p>Bronchodilator therapy has no role in treatment of children with parapneumonic effusions and may potentially worsen their ventilation-perfusion (V/Q) mismatch, exacerbating hypoxemia. Chest physiotherapy is not recommended [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H242598983"><span class="h1">ANTIBIOTIC THERAPY</span></p><p class="headingAnchor" id="H242599050"><span class="h2">Choice of agent</span><span class="headingEndMark"> — </span>All children with parapneumonic effusion should be treated with antibiotic therapy. In children with a small effusion, this may include broad-spectrum oral antibiotics and close observation on an outpatient basis [<a href="#rid5">5</a>].</p><p>Children with moderate to large effusions or empyema require hospitalization and treatment with intravenous (IV) antibiotics in doses adequate to ensure pleural penetration [<a href="#rid2">2</a>]. If drainage of pleural fluid is indicated, pleural fluid should be sent for bacterial cultures and Gram stain to help direct antibiotic therapy. Additional techniques may be used to increase the yield of microbiologic diagnosis, especially in children who have received antibiotics. These include direct and enrichment culture for aerobic and anaerobic organisms, pneumococcal antigen detection (latex agglutination), and specific or broad-range polymerase chain reaction (PCR) testing. Preferably, the culture should be sent prior to beginning antibiotics if this does not delay treatment. However, cultures can still be helpful even if the patient has been on antibiotics prior to the sampling of pleural fluid. (See <a class="local">'Overview of management'</a> below.)</p><p>The initial choice of antibiotic(s) should be empiric, informed by considerations of the most common organisms causing community-acquired or nosocomial pneumonia in the patient's age group in his/her community or hospital, respectively. Antibiotic therapy should be modified based upon the sensitivity results if and when they are available.</p><p class="headingAnchor" id="H242602975"><span class="h3">Community-acquired infection</span></p><p class="bulletIndent1"><span class="glyph">●</span>For outpatients (ie, those with a small effusion who are clinically well), empiric antibiotic regimens are the same as for pediatric community-acquired pneumonia. The considerations are summarized in the table (<a class="graphic graphic_table graphicRef80561" href="/z/d/graphic/80561.html" rel="external">table 1</a>) and detailed in a separate topic review. (See  <a class="medical medical_review" href="/z/d/html/5987.html" rel="external">"Community-acquired pneumonia in children: Outpatient treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For inpatients, suggested empiric therapy is IV <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">ceftriaxone</a> or <a class="drug drug_pediatric" data-topicid="13129" href="/z/d/drug information/13129.html" rel="external">cefotaxime</a> (where available), <strong>plus</strong> <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">clindamycin</a> or <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">vancomycin</a> if <em>Staphylococcus aureus</em> or anaerobes are a consideration. The choice of first-line antibiotics is mainly determined by the most common bacteriologic etiology causing community-acquired pneumonia in a given area. Antibiotic selection is summarized in the table (<a class="graphic graphic_table graphicRef56260 graphicRef127763" href="/z/d/graphic/56260.html" rel="external">table 2A-B</a>) and detailed in a separate topic review. (See  <a class="medical medical_review" href="/z/d/html/6054.html" rel="external">"Pneumonia in children: Inpatient treatment", section on 'Complicated CAP'</a>.)</p><p></p><p class="bulletIndent1">For ill-appearing children, it is particularly important to include <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">vancomycin</a> or <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">clindamycin</a> in the regimen because of the increasing frequency of parapneumonic effusions caused by community-associated methicillin-resistant <em>S</em>.<em> aureus</em> (CA-MRSA) [<a href="#rid7">7-9</a>]. Vancomycin remains the drug of choice to treat MRSA. However, other antibacterial agents, such as clindamycin, can be used if the organism is sensitive to them. The use of newer anti-MRSA antibiotics should be reserved for the most resistant cases. (See  <a class="medical medical_review" href="/z/d/html/6057.html" rel="external">"<i>Staphylococcus aureus </i>in children: Overview of treatment of invasive infections", section on 'MRSA infections'</a>.)</p><p></p><p class="headingAnchor" id="H242602986"><span class="h3">Hospital-acquired infection</span><span class="headingEndMark"> — </span>Empiric antibiotic therapy for children with hospital-acquired (nosocomial) parapneumonic effusion should include coverage for Gram-negative organisms. If aspiration is suspected (ie, in children with underlying neuromuscular disease or neurologic impairment), coverage for oral anaerobes is recommended. (See  <a class="medical medical_review" href="/z/d/html/6054.html" rel="external">"Pneumonia in children: Inpatient treatment"</a>.)</p><p class="headingAnchor" id="H242599270"><span class="h2">Duration</span><span class="headingEndMark"> — </span>The duration of antibiotic therapy should be individualized, depending on the adequacy of fluid drainage and the clinical response of the patient [<a href="#rid5">5</a>]. Common practice is to continue antibiotics for at least 10 days after resolution of fever; antibiotics may be changed from the IV to oral route when the child has been afebrile and without a chest drain for two to five days, or possibly sooner if close clinical follow-up is assured [<a href="#rid2">2</a>]. For community-acquired pneumonia associated with a parapneumonic effusion or empyema, oral antibiotics appear to be as effective as IV antibiotics after hospital discharge [<a href="#rid10">10-12</a>]. Moreover, oral antibiotics avoid potential complications that can be associated with IV catheters. For most cases of parapneumonic effusion or empyema, a total antibiotic course of two to four weeks is adequate [<a href="#rid5">5,13</a>]. Infections caused by certain pathogens, including CA-MRSA, may require a longer course of treatment.</p><p class="headingAnchor" id="H2896459239"><span class="h1">FREE-FLOWING PLEURAL FLUID</span></p><p class="headingAnchor" id="H242599471"><span class="h2">Small parapneumonic effusion</span><span class="headingEndMark"> — </span>A small pleural effusion is generally defined by its appearance on chest radiograph as fluid occupying &lt;1 cm on lateral decubitus radiograph or opacifying less than one-fourth of the hemithorax [<a href="#rid5">5</a>]. Children with effusions of this size who are well-appearing and in no respiratory distress can be managed as outpatients, with broad-spectrum oral antibiotics and close observation with chest radiographs (<a class="graphic graphic_algorithm graphicRef78748" href="/z/d/graphic/78748.html" rel="external">algorithm 1</a>) [<a href="#rid5">5</a>]. (See <a class="local">'Antibiotic therapy'</a> above.)</p><p>Even if the effusion is small, hospital admission and intravenous (IV) antibiotics are appropriate for patients who are ill-appearing, in respiratory distress, under six months of age, have evidence of bacteremia/sepsis, or have failed outpatient management. (See <a class="local">'Hospitalization'</a> above.)</p><p class="headingAnchor" id="H242600537"><span class="h2">Moderate or large simple effusion (not loculated)</span><span class="headingEndMark"> — </span>A moderate or large pleural effusion is typically defined as fluid occupying &gt;1 cm on lateral decubitus radiograph or opacifying more than one-fourth of the hemithorax [<a href="#rid5">5</a>]. Such patients should be further evaluated with ultrasonography to determine whether the fluid is free-flowing (simple effusion) or loculated.</p><p class="headingAnchor" id="H3084164220"><span class="h3">Overview of management</span><span class="headingEndMark"> — </span>Recommendations for management of parapneumonic effusion and empyema have been developed by the British Thoracic Society (BTS), the American Pediatric Surgical Association (APSA), and the Pediatric Infectious Diseases Society (PIDS) [<a href="#rid2">2,5,14</a>]. These approaches are similar, as summarized in the algorithm (<a class="graphic graphic_algorithm graphicRef76277" href="/z/d/graphic/76277.html" rel="external">algorithm 2</a>):</p><p>Patients with simple effusions (free-flowing fluid) can be treated with drainage and empirically selected IV antibiotics, which are subsequently adjusted based on polymerase chain reaction (PCR) or culture and sensitivity results. In our practice, we insert a pigtail catheter (small-bore catheter), which allows for continuous drainage. Continuous drainage (rather than antibiotics alone or simple thoracentesis) is particularly important if the patient has significant respiratory compromise or if the effusion is very large (eg, occupying more than one-half of the hemithorax), as determined by thoracic ultrasound. Patients who do not have a good clinical or radiologic response within 24 to 48 hours are likely progressed to loculated fluid or empyema and will need to be treated accordingly.</p><p>Whenever drainage is done, a fluid sample should be sent for cultures and Gram stain to help direct antibiotic therapy. Additional techniques may be used to increase the yield of microbiologic diagnosis in children who have received antibiotics. These include direct and enrichment culture for aerobic and anaerobic organisms, pneumococcal antigen detection (latex agglutination), and specific or broad-range PCR. Measurement of other characteristics of the pleural fluid, such as pH, glucose, and lactate dehydrogenase (LDH), may be helpful if the diagnosis of empyema is in doubt or in the setting of an underlying condition that might be responsible for the effusion, such as collagen vascular disease. Routine measurement of these characteristics is not recommended. Although they have been used to predict a need for drainage procedures, the results rarely change management of a patient with community-acquired pneumonia [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/z/d/html/6344.html" rel="external">"Epidemiology, clinical presentation, and evaluation of parapneumonic effusion and empyema in children", section on 'Microbial analysis'</a>.)</p><p>As an alternative, a trial of antibiotics without drainage has been suggested for clinically stable patients with moderate and, occasionally in selected patients, large effusions. This approach was evaluated in hospitalized children who were stable and clinically well with no need for oxygen supplementation and no signs of severe respiratory distress. These children were treated with a trial of empirically selected antibiotics for a 24- to 72-hour period without undergoing a drainage procedure; patients who did not respond clinically proceeded to chest tube placement or surgical drainage [<a href="#rid15">15</a>]. Antibiotics alone were successful in approximately one-half of these children.</p><p class="headingAnchor" id="H1287546626"><span class="h3">Thoracentesis</span><span class="headingEndMark"> — </span>Simple thoracentesis is rarely used for management of parapneumonic effusion in children. However, it is occasionally used to obtain pleural fluid for diagnostic purposes, in cases where continuous drainage via pigtail catheter is not anticipated and if empiric selection of antibiotics is not considered sufficient.</p><p>Thoracentesis has also been used therapeutically to drain moderate or large simple effusions in clinically stable patients, but in most institutions, the procedure has been replaced by continuous drainage via a pigtail catheter (see <a class="local">'Chest tubes'</a> below). When thoracentesis is used therapeutically, as much fluid as possible is slowly removed (up to 10 to 20 mL/kg). Insertion of a pigtail catheter or chest tube is warranted if reaccumulation of fluid occurs after the initial thoracentesis or if the effusion is very large (eg, occupying more than one-half of the hemithorax). Repeated thoracentesis is not recommended [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H14"><span class="h3">Chest tubes</span><span class="headingEndMark"> — </span>Large amounts of pleural fluid can be slowly drained using chest tubes (typically pigtail catheter) with underwater seal systems. The chest tube is left in place until fluid drainage becomes minimal. Details of placement and management of chest tubes are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7816.html" rel="external">"Thoracostomy tubes and catheters: Indications and tube selection in adults and children"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – Indications for chest tube placement include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Large amounts of free-flowing pleural fluid – We generally insert a small-bore chest tube (pigtail catheter) for large effusions (eg, occupying more than one-half of the hemithorax), even in the absence of respiratory compromise.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Compromised pulmonary function – eg, respiratory distress, hypoxemia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Loculated effusion – Loculation of fluid on initial or follow-up imaging or other evidence of fibrinopurulent effusions (eg, positive Gram stain, frank pus, or pH &lt;7.0, glucose &lt;40 mg/dL [2.22 mmol/L], LDH &gt;1000 international units [16.67 kat/L], if these characteristics were measured) [<a href="#rid16">16</a>]. If these features are present, we suggest adjunctive fibrinolytic therapy or proceeding to video-assisted thoracoscopic surgery (VATS). (See <a class="local">'Loculated effusion or empyema'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lack of clinical improvement – For patients treated with a trial of antibiotic therapy without drainage, chest tube placement is indicated if there is no improvement (eg, fever that fails to respond to 48 to 72 hours of antibiotic therapy) or if the fluid reaccumulates or increases after thoracentesis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Size of tube</strong> – Smaller chest tubes (eg, &lt;14F, including pigtail catheters) are now generally recommended over large-bore tubes to minimize patient discomfort [<a href="#rid2">2,14</a>]. In the past, smaller tubes were often avoided because they were thought to be more prone to obstruction by fibrinopurulent exudate, but clinical studies have failed to substantiate this concern, especially when fibrinolytics are used in addition to chest tube drainage [<a href="#rid17">17,18</a>]. Furthermore, when combined with fibrinolytic therapy, the use of small chest tubes may provide some advantages over large tubes [<a href="#rid19">19,20</a>]. (See  <a class="medical medical_review" href="/z/d/html/7816.html" rel="external">"Thoracostomy tubes and catheters: Indications and tube selection in adults and children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Placement</strong> – Ultrasonography can be used to guide chest tube placement. The procedure can be performed at the same time as the ultrasonography, or the skin can be marked to indicate the optimum site for drain insertion [<a href="#rid21">21-24</a>]. A fluid sample should be sent for cultures and Gram stain to help direct antibiotic therapy. (See  <a class="medical medical_review" href="/z/d/html/126623.html" rel="external">"Thoracostomy tubes and catheters: Placement techniques and complications"</a>.)</p><p></p><p class="bulletIndent1">A chest radiograph is typically obtained after insertion of the chest tube to ensure that there is no pneumothorax and to verify position [<a href="#rid2">2</a>]. However, an effectively functioning chest tube should not be repositioned solely on the basis of a radiograph [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – All chest tubes should be connected to a unidirectional drainage system, which must be kept below the level of the patient's chest at all times [<a href="#rid2">2</a>]. The underwater seal system is frequently used. This system is comprised of a tube placed underwater at a depth of approximately 1 to 2 cm and a side vent, which either permits escape of air or is connected to a suction pump [<a href="#rid2">2</a>]. The system should be assessed daily for the amount of drainage, the presence of bubbling, and the presence of swing in the fluid with respiration (which confirms tube patency and appropriate position in the pleural cavity).</p><p></p><p class="bulletIndent1">Large effusions should be drained gradually. We suggest clamping the drain for one hour after drainage of the initial 10 mL/kg of pleural fluid. In large children and adolescents, some experts suggest that no more than 1500 mL of fluid should be drained at one time and that drainage should be limited to 500 mL/hour, although there is no specific evidence on which to base this suggestion [<a href="#rid2">2,26</a>]. These precautions are suggested because very rapid drainage of pleural fluid occasionally causes pulmonary edema (known as "reexpansion pulmonary edema"). This complication has been reported after drainage of large effusions in adults [<a href="#rid27">27</a>] and in children with malignant lymphoma [<a href="#rid28">28</a>] but is otherwise rare in children.</p><p></p><p class="bulletIndent1">Clamped drains must be immediately unclamped if there are any signs of clinical deterioration (eg, breathlessness, chest pain). This could be caused by tension pneumothorax in patients with air leak (which may be subclinical) [<a href="#rid2">2</a>] or by rapid accumulation of fluid.</p><p></p><p class="bulletIndent1">Continuous bubbling from a chest drain suggests a continued visceral pleural air leak, which may develop into a tension pneumothorax if the chest drain is clamped. Therefore, a bubbling chest drain should not be clamped [<a href="#rid2">2,26</a>]. If continuous bubbling is present while the chest tube is connected to suction, the position of the tube should be assessed since it may be partly out of the thorax with one of its drainage holes open to the atmosphere [<a href="#rid2">2</a>]. Continuous bubbling may also be caused by a bronchopleural fistula, especially in cases of necrotizing pneumonia, a complication that sometimes requires surgical intervention.</p><p></p><p class="bulletIndent1">Routine daily chest radiographs are not needed, since radiographic findings lag behind clinical status [<a href="#rid3">3</a>]. Repeat chest radiographs as indicated by changes in clinical status or after interventions (ie, removal of suction or clamping).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Troubleshooting</strong> – Sudden cessation of fluid drainage may indicate kinking or blockage of the tube by thick exudative fluid, pus, or debris [<a href="#rid2">2</a>]. Small soft drains are prone to kinking at the exit site, particularly in young, mobile children. Obstruction of the tube by pus may be relieved by carefully flushing with normal <a class="drug drug_pediatric" data-topicid="12796" href="/z/d/drug information/12796.html" rel="external">saline</a> (10 mL should be adequate in a small-bore drain) [<a href="#rid2">2</a>]. A drain that cannot be unblocked is to be removed and replaced if significant pleural fluid remains [<a href="#rid2">2</a>]. In addition, drainage may cease if the fluid becomes loculated or the suction holes of the tube are outside the pleural space [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Removal</strong> – The chest tube can be removed once there is clinical resolution and minimal chest tube drainage (less than 10 to 15 mL per 24 hours) [<a href="#rid2">2,5,6</a>]. It is not necessary to wait for complete resolution of drainage, since the tube itself may act as a stimulus for pleural exudative reaction and increases the risk of secondary infection. There is no need to do a trial of clamping the chest tube before its removal [<a href="#rid2">2</a>]. Clinical factors indicating a response to therapy include resolution of fever, with decreasing white blood cell count and C-reactive protein (CRP), decreasing respiratory and heart rates, and improvement in appetite and sense of well-being.</p><p></p><p class="bulletIndent1">Analgesia can be used for chest tube removal, and sedation may be necessary in young children [<a href="#rid2">2</a>]. Local anesthetic cream applied to the adjacent skin three hours before chest tube removal may be as effective as IV <a class="drug drug_pediatric" data-topicid="16024" href="/z/d/drug information/16024.html" rel="external">morphine</a> for pain control [<a href="#rid29">29</a>]. The chest tube is removed with a brisk, firm movement while the child performs the Valsalva maneuver or during expiration [<a href="#rid2">2</a>]. A chest radiograph is typically performed after chest tube removal to check for pneumothorax.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications</strong> – Complications of chest tubes are rare, especially with use of small tubes (pigtail catheters), and can include bleeding, wound infection at the exit site, development of bronchopleural fistula, persistent atelectasis, and laceration of the lung [<a href="#rid24">24,30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Failure to respond</strong> – With appropriate therapy, children with symptomatic parapneumonic effusion can be expected to improve within the first few days of treatment [<a href="#rid6">6,31</a>]. If the child remains febrile or tachypneic and aeration does not improve, the chest tube may be obstructed or failing to drain because of the development of loculations, as described above [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1">For patients who do not have a good clinical response within 24 to 48 hours to management with antibiotics with chest tube drainage, we suggest advancing to the therapies used for loculated fluid or empyema (ie, either fibrinolytic therapy or VATS). At some institutions, a repeat ultrasound is performed to evaluate for loculation before advancing therapy. At other institutions, therapy is advanced empirically. (See <a class="local">'Loculated effusion or empyema'</a> below.)</p><p></p><p class="headingAnchor" id="H242600517"><span class="h1">LOCULATED EFFUSION OR EMPYEMA</span><span class="headingEndMark"> — </span>Patients who have evidence of loculated fluid on the initial ultrasound require more aggressive intervention to drain the fluid and clear the infection. Expert opinion regarding the optimal type and timing of drainage and surgical intervention continues to evolve, and management remains somewhat controversial. The main options are fibrinolytic therapy and surgical debridement of the pleural space.</p><p>Management approaches described below are consistent with guidelines from the American Pediatric Surgical Association (APSA) and British Thoracic Society (BTS) [<a href="#rid2">2,14</a>]. Additional recommendations from the BTS guidelines are shown in the table (<a class="graphic graphic_table graphicRef78355" href="/z/d/graphic/78355.html" rel="external">table 3</a>).</p><p class="headingAnchor" id="H1300028355"><span class="h2">Intrapleural fibrinolytics versus surgical treatment</span><span class="headingEndMark"> — </span>Either intrapleural fibrinolytic therapy (pleural catheter placement with instillation of fibrinolytics) or surgical treatment (typically video-assisted thoracoscopic surgery [VATS]) is acceptable as first-line therapy for children with loculated effusions. However, we suggest a trial of fibrinolytic therapy as the initial treatment of choice, followed by VATS for those failing pleural drainage with fibrinolytics, consistent with BTS and APSA guidelines [<a href="#rid2">2,14</a>]. This suggestion is based on limited evidence, and most experts agree that either approach is reasonable. The choice may be influenced by available expertise, cost considerations, and patient preferences.</p><p>Pleural drainage with fibrinolytics is successful in approximately 83 percent of children; the remaining 17 percent who fail medical therapy will require VATS, as shown in the following randomized trials:</p><p class="bulletIndent1"><span class="glyph">●</span>A randomized trial in Europe compared VATS with medical therapy with fibrinolysis and found no difference in clinical outcome [<a href="#rid32">32</a>]. In this trial, 60 children (&lt;16 years) with radiographic evidence of empyema and indications for drainage were randomly assigned to treatment with primary VATS or percutaneous chest tube drainage with intrapleural urokinase. The primary outcome measure was length of hospital stay after intervention, and there was no difference between groups (95% CI -2 to 1 day). The median hospital stay after intervention was six days for both groups, with a range of 3 to 16 days for those treated with VATS and 4 to 25 days for those randomized to fibrinolysis. Hospital costs were 25 percent higher for the group treated with primary VATS versus those randomized to primary fibrinolysis. Of note, the fibrinolytic used in this trial was urokinase, which is less expensive than the fibrinolytic agents commonly used in the United States and some other countries.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similar findings were shown in a randomized trial from the United States, in which 36 children were randomized to initial treatment with primary VATS or fibrinolysis with <a class="drug drug_pediatric" data-topicid="13363" href="/z/d/drug information/13363.html" rel="external">alteplase</a> (recombinant human tissue plasminogen activator [tPA]) [<a href="#rid33">33</a>]. The failure rate of fibrinolysis was 16.6 percent (3 of 18 subjects), and two patients treated with primary VATS required ventilator support after surgery. There was no difference in median hospital stay after intervention, but hospital costs were substantially lower for the group treated with primary fibrinolysis (USD $11,700 versus $7,600).</p><p></p><p>Thus, long-term outcomes are excellent for all treatment plans (antibiotics alone, pleural catheters with fibrinolytics, and VATS), but surgical therapy with VATS is associated with higher treatment costs and requires special expertise. Before these randomized trials were published, many institutions preferred to use primary surgical therapy because this approach appeared to reduce duration of therapy with chest tube (10.6 versus 4.4 days), hospital stay (20 versus 10.8 days), and antibiotic therapy (21.3 versus 12.8 days) and mortality (3.3 versus 0 percent), based on a systematic review of observational studies summarized in the table (<a class="graphic graphic_table graphicRef73858" href="/z/d/graphic/73858.html" rel="external">table 4</a>) [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H21"><span class="h2">Fibrinolytic therapy</span><span class="headingEndMark"> — </span>The use of fibrinolytic drugs to lyse the fibrinous strands in loculated parapneumonic effusions has been described in adults and children. These drugs include urokinase, <a class="drug drug_pediatric" data-topicid="13363" href="/z/d/drug information/13363.html" rel="external">alteplase</a> (tPA), or streptokinase.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – The evidence supporting fibrinolysis as a component of medical therapy for complicated parapneumonic effusion comes from randomized trials and meta-analyses comparing various fibrinolytic therapies with normal <a class="drug drug_pediatric" data-topicid="12796" href="/z/d/drug information/12796.html" rel="external">saline</a>, and weakly favors fibrinolytic therapy:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A meta-analysis in adults with loculated effusions or empyema found a nonsignificant improvement in outcomes with fibrinolytic therapy compared with <a class="drug drug_pediatric" data-topicid="12796" href="/z/d/drug information/12796.html" rel="external">saline</a> (pooled risk ratio 0.55, 95% CI 0.28-1.07) [<a href="#rid35">35</a>]. A separate meta-analysis analyzing the same trials using different methods found that fibrinolytics reduced the need for surgical intervention (pooled risk ratio 0.63, 95% CI 0.46-0.85) [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A randomized study in children examined the effect of intrapleural <a class="drug drug_pediatric" data-topicid="13363" href="/z/d/drug information/13363.html" rel="external">alteplase</a> versus normal <a class="drug drug_pediatric" data-topicid="12796" href="/z/d/drug information/12796.html" rel="external">saline</a> on 17 children with parapneumonic effusion (&gt;20 percent of pleural cavity or &gt;2 cm thickness on CT scan) who underwent chest tube placement [<a href="#rid37">37</a>]. Nine subjects received alteplase on day 1 and 3 and saline on day 2 and 4, and eight patients received the alteplase on day 2 and 4 with saline on the alternate days. Pleural drainage was increased on the days that alteplase was administered compared with days when normal saline was used.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice of agent</strong> – No controlled studies are available to determine whether any one of the fibrinolytic agents is more effective than the others. The choice of agent depends upon availability, with urokinase being preferred if it is available, followed by <a class="drug drug_pediatric" data-topicid="13363" href="/z/d/drug information/13363.html" rel="external">alteplase</a> (tPA) and streptokinase. Addition of the mucolytic agent deoxyribonuclease (DNase; eg, dornase alfa) to the fibrinolytic regimen has no benefit in length of hospital stay or other outcomes, based on a randomized trial in children [<a href="#rid38">38</a>], although it appears to enhance treatment in adults [<a href="#rid39">39</a>]. (See  <a class="medical medical_review" href="/z/d/html/119384.html" rel="external">"Management and prognosis of parapneumonic pleural effusion and empyema in adults", section on 'Intrapleural tPA +/- additional drainage'</a>.)</p><p></p><p class="bulletIndent1">Only urokinase has been studied in a placebo-controlled fashion in children and thus is recommended by the BTS [<a href="#rid2">2</a>]. In North America, urokinase is no longer available, so <a class="drug drug_pediatric" data-topicid="13363" href="/z/d/drug information/13363.html" rel="external">alteplase</a> is usually used. This approach is supported by a retrospective case series showing similar outcomes and increased thoracostomy tube drainage with alteplase compared with urokinase [<a href="#rid40">40</a>]. Streptokinase is generally considered a third-line choice because of limited efficacy in one large trial and reports of occasional allergic reactions [<a href="#rid2">2,41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Technique and dose</strong> – Fibrinolytic therapy is administered by instilling the drug through the chest tube, or via irrigation at the time of thoracoscopy. In most cases, we administer fibrinolytic therapy through a pigtail catheter, inserted under ultrasound guidance using light sedation. The treatment may cause discomfort, and adequate sedation and or analgesia need to be provided.</p><p></p><p class="bulletIndent1">A number of different doses of these agents have been used in various studies. Two approaches for treatment with <a class="drug drug_pediatric" data-topicid="13363" href="/z/d/drug information/13363.html" rel="external">alteplase</a> were described in the Pediatric Infectious Diseases Society (PIDS) guideline, based on clinical studies in which these regimens were shown to be safe and effective in children older than three months of age [<a href="#rid5">5</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13363" href="/z/d/drug information/13363.html" rel="external">Alteplase</a> 4 mg in 40 mL 0.9% <a class="drug drug_pediatric" data-topicid="12796" href="/z/d/drug information/12796.html" rel="external">saline</a>, intrapleural, with one-hour dwell time; repeat every 24 hours for three days (total of three doses) [<a href="#rid14">14,33</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13363" href="/z/d/drug information/13363.html" rel="external">Alteplase</a> 0.1 mg/kg (maximum 3 mg) in 10 to 30 mL 0.9% <a class="drug drug_pediatric" data-topicid="12796" href="/z/d/drug information/12796.html" rel="external">saline</a>, intrapleural, with a 45-minute to one-hour dwell time, and repeated every eight hours for three days (total of nine doses) [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1">The following technique and dose for urokinase is recommended in the BTS guidelines [<a href="#rid2">2</a>] and is also included in the PIDS guideline [<a href="#rid5">5</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Urokinase 40,000 units in 40 mL 0.9% <a class="drug drug_pediatric" data-topicid="12796" href="/z/d/drug information/12796.html" rel="external">saline</a> for children one year and older, and 10,000 units in 10 mL 0.9% saline for children younger than one year. This dose should be administered twice daily (with a four-hour dwell time) for three days; additional doses can be administered if the response is incomplete after six doses. Intrapleural <a class="drug drug_pediatric" data-topicid="13100" href="/z/d/drug information/13100.html" rel="external">bupivacaine</a> (0.5 to 1.0 mL/kg of a 0.25% solution) can be administered with urokinase if the child finds it uncomfortable [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contraindications</strong> – Fibrinolytic therapy should not be performed in patients who have bronchopleural fistula or chest tubes that are bubbling (suggestive of an air leak), since clamping of the chest tube in such a patient could result in tension pneumothorax. In addition, chest tubes that are clamped must be immediately unclamped if the child has any signs of clinical deterioration (eg, breathlessness, chest pain). (See <a class="local">'Chest tubes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Adverse effects of fibrinolytic therapy include fever, discomfort, intrapleural bleeding, and anaphylaxis [<a href="#rid19">19,40,43</a>]. In the pediatric trials using urokinase and/or <a class="drug drug_pediatric" data-topicid="13363" href="/z/d/drug information/13363.html" rel="external">alteplase</a> described above, minor side effects included discomfort during intrapleural injection and transient blood staining of the drainage fluid [<a href="#rid19">19,40</a>]. Rare immediate hypersensitivity reactions to urokinase have been reported in adults [<a href="#rid44">44</a>]. Intrapleural administration of streptokinase generates a systemic antibody response similar to that when the drug is administered intravenously (IV) [<a href="#rid45">45</a>]; fever has been reported and other immunologic responses are possible.</p><p></p><p class="headingAnchor" id="H27"><span class="h2">Surgical therapy</span><span class="headingEndMark"> — </span>Surgical intervention may be used as first-line therapy for patients with loculated effusions or empyema, or a secondary therapy for those failing fibrinolytic therapy. Most experts agree that either approach is reasonable, and the choice may be influenced by available expertise, cost considerations, and patient preferences. In either case, early involvement of a surgeon in the decision-making process helps to ensure that timely surgical intervention can be performed if it is indicated [<a href="#rid2">2</a>]. (See <a class="local">'Intrapleural fibrinolytics versus surgical treatment'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – Situations in which surgical intervention usually is necessary include [<a href="#rid2">2</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lack of clinical improvement, including signs of persistent sepsis and persistent pleural collection after initial management (eg, antibiotics, chest tube drainage, and fibrinolytic therapy for three to four days)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Complex empyema with significant lung pathology (eg, development of a thick fibrous pleural rind, sometimes termed a "peel," which may "trap" the lung and prevent lung reexpansion)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bronchopleural fistula with pyopneumothorax</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Video-assisted thorascopic surgery</strong> – VATS is the preferred procedure for surgical drainage in typical patients if expertise in this technique is available because it is less invasive than open thoracotomy [<a href="#rid2">2</a>]. A chest drain is left in place after the procedure for continued drainage of fluid or pus.</p><p></p><p class="bulletIndent1">VATS can be used to remove the thick fibrinous septations that prevent adequate drainage of pleural fluid via chest tube. VATS permits debridement of fibrinous pyogenic material, breakdown of loculations [<a href="#rid46">46-48</a>], and drainage of pus from the pleural cavity under direct vision [<a href="#rid2">2,49-51</a>]. Contraindications to VATS include inability to develop a pleural window to access the pleural cavity, the presence of thick pyogenic material, and/or fibrotic pleural rinds [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1">Observational studies and case series suggest that VATS has good outcomes in efficacy and safety, and the procedure is commonly performed in children with empyema in centers where appropriate expertise is available [<a href="#rid2">2,46,47,52-56</a>]. Compared with open thoracotomy, VATS is less invasive and is associated with shorter duration of analgesia, chest tubes, and postoperative length of stay [<a href="#rid16">16,46,47,57,58</a>]. VATS leaves two to three small scars [<a href="#rid2">2,59</a>]. The use of VATS depends to a large extent upon the availability of the equipment and appropriately trained pediatric thoracic surgeons [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1">Compared with antibiotics and drainage, with or without fibrinolysis, VATS is more invasive and costly but has a lower failure rate. These competing considerations lead to ongoing controversy as to the relative benefits of medical therapy versus early VATS in children with parapneumonic effusion and empyema:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Proponents of early VATS suggest that if general anesthesia is necessary for simple drain insertion, the procedure may as well be combined with VATS if an appropriately trained surgeon is available [<a href="#rid49">49</a>]. Early VATS is reported to enhance the chance of full expansion of the collapsed lung [<a href="#rid49">49-51</a>]. Some data suggest that the failure rate increases in late-presenting cases [<a href="#rid50">50,57</a>] and in patients who undergo VATS after failure of urokinase therapy [<a href="#rid59">59-61</a>].</p><p></p><p class="bulletIndent2">Compared with drainage without fibrinolysis, early VATS appears to decrease the length of hospitalization. As an example, one study concluded that early VATS (&lt;48 hours after admission) compared with late VATS (&gt;48 hours after admission) significantly decreased the length of hospitalization (11.5 versus 15.2 days) [<a href="#rid53">53</a>]. Similar findings have been reported in other retrospective studies [<a href="#rid54">54,62</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Proponents of a trial of pleural drain/fibrinolytics point out that this approach is successful in a majority of patients, thus avoiding the need for surgery. When pleural drain placement includes fibrinolysis, it is effective in more than 80 percent of children, with similar length of stay and lower costs compared with early VATS. As a result, a trial of fibrinolysis is suggested for most patients with loculated effusion or empyema; supporting data and rationale are discussed above. (See <a class="local">'Intrapleural fibrinolytics versus surgical treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other techniques</strong> – Other surgical techniques are used in selected patients but are rarely required in children.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Minithoracotomy – Minithoracotomy achieves debridement and evacuation in a manner similar to VATS [<a href="#rid2">2</a>]. However, minithoracotomy is an open procedure that uses a conventional surgical approach but the incision length is considerably reduced compared with a typical thoracotomy incision.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Decortication – Decortication involves an open posterolateral thoracotomy and excision of the thick fibrous pleural rind with evacuation of pyogenic material. This is a longer and more complicated procedure than minithoracotomy, leaves a larger linear scar along the rib line, and may promote subsequent development of scoliosis [<a href="#rid2">2,63</a>].</p><p></p><p class="bulletIndent2">Decortication is rarely necessary in children with empyema since most, if not all, ultimately return to baseline lung function. The procedure may be necessary for children with late-presenting empyema and significant fibrous pleural rind ("peel"), complex empyema, and chronic empyema, and/or if VATS fails [<a href="#rid2">2,64</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Medical thoracoscopy – Medical thoracoscopy has been used as an alternative to VATS in adults with pleural diseases including empyema; this procedure is performed by pulmonologists rather than surgeons and is usually done under light sedation. Medical thoracoscopy is not generally used in children, because of lack of safety data and technical difficulties including trocar size. The use of this procedure in adults is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4388.html" rel="external">"Medical thoracoscopy (pleuroscopy): Equipment, procedure, and complications"</a>.)</p><p></p><p class="headingAnchor" id="H2920744070"><span class="h1">INVESTIGATIONAL THERAPY</span><span class="headingEndMark"> — </span>Systemic glucocorticoids have been investigated as adjunctive treatment for parapneumonic effusions. We do not use this strategy, because of limited and conflicting evidence for benefit and potential adverse effects.</p><p>The use of intravenous (IV) <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a> as an adjunct therapy in parapneumonic pleural effusion was explored in a randomized trial in 60 children (1 month to 14 years) with parapneumonic effusion (18 with simple effusion, 12 with complicated effusion in each group) [<a href="#rid65">65</a>]. After adjustment by severity group and stratification by center, children treated with dexamethasone had shorter median time to recovery compared with placebo (109 versus 177 hours, respectively; hazard ratio 1.95, 95% CI 1.10-3.45). The benefit was primarily for children with simple rather than loculated parapneumonic effusions. Dexamethasone increased the risk for hyperglycemia, but there were no other significant differences in adverse events. Limitations of this study include some imbalance in baseline characteristics between the groups that may have influenced the outcomes and insufficient sample size to distinguish between subgroups with simple effusion versus complicated effusions. A study in adults found no benefit of systemic glucocorticoids [<a href="#rid66">66</a>].</p><p class="headingAnchor" id="H34"><span class="h1">OUTPATIENT FOLLOW-UP</span><span class="headingEndMark"> — </span>After hospital discharge, children with parapneumonic effusion or empyema should be seen in follow-up to ensure full recovery and complete resolution of symptoms. We perform chest radiography (posteroanterior and lateral) at this point for patients with residual symptoms or those who had particularly severe disease at presentation. Patients should be followed until they have recovered completely and their chest radiograph has returned to near normal, which usually occurs by three to six months [<a href="#rid2">2,6,67-69</a>] but may take as long as 16 months [<a href="#rid70">70</a>]. Patients may have residual dullness to percussion and diminished breath sounds over the affected areas because of pleural thickening [<a href="#rid2">2,71,72</a>].</p><p>Evaluation for underlying predisposing conditions, such as immune disorders, should be considered in children who have a history of recurrent bacterial infections or poor growth [<a href="#rid2">2,73,74</a>]. (See  <a class="medical medical_review" href="/z/d/html/6367.html" rel="external">"Cystic fibrosis: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5949.html" rel="external">"Approach to the child with recurrent infections"</a>.)</p><p class="headingAnchor" id="H35"><span class="h1">PROGNOSIS AND OUTCOME</span><span class="headingEndMark"> — </span>Despite the marked abnormalities at the time of presentation and the variety of treatment approaches, the majority of children with parapneumonic effusion or empyema make a complete recovery [<a href="#rid34">34,75,76</a>]. Those with empyema, particularly empyema caused by <em>S</em>.<em> aureus</em>, anaerobic bacteria, or group A <em>Streptococcus</em> (<em>Streptococcus pyogenes</em>), typically have a more delayed recovery [<a href="#rid6">6</a>]. There is no evidence that cases caused by antibiotic-resistant organisms are associated with poorer outcomes [<a href="#rid52">52</a>], although length of hospital stay may be increased [<a href="#rid53">53</a>]. If necrotizing pneumonia develops, this may be complicated by bronchopleural fistula and tension pneumothorax, or perforation through the chest wall (empyema necessitatis) [<a href="#rid2">2</a>]. These complications are rare, but if they occur, recovery is prolonged.</p><p>In a systematic review comparing primary operative and nonoperative therapy in 3418 children with empyema, the mortality rate for children treated with antibiotics and chest tubes was 3.3 percent; no deaths were reported among the 363 children treated with fibrinolytic therapy, video-assisted thoracoscopic surgery (VATS), or thoracotomy [<a href="#rid34">34</a>]. Mortality is higher for children younger than one to two years of age [<a href="#rid71">71,77,78</a>]. Mortality also is increased in patients with underlying disease (eg, aspiration, malnutrition), particularly if treatment is delayed.</p><p>Long-term follow-up studies suggest that fewer than 10 percent of children have residual symptoms [<a href="#rid70">70,76,79</a>]. The rate of residual radiologic or pulmonary function abnormalities is higher, but these abnormalities are usually mild, and most of these patients are asymptomatic and have normal exercise tolerance. As an example, among 51 children examined at least two years after recovery from parapneumonic effusion, there were small abnormalities in lung function and exercise capacity, which were of no clinical importance [<a href="#rid80">80</a>]. All of the children in this report had been managed with medical therapy alone: 73 percent with chest tube drainage and 33 percent with drainage and fibrinolysis. In another observational study of 36 children with empyema, mild spirometry abnormalities were observed soon after discharge and returned to normal within five years [<a href="#rid81">81</a>]. The study detected no differences in spirometry outcomes between the groups that had been managed with chest tube (with or without fibrinolysis) versus VATS.</p><p class="headingAnchor" id="H581025940"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110776.html" rel="external">"Society guideline links: Pediatric pneumonia"</a>.)</p><p class="headingAnchor" id="H36"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Although approaches vary, there is a growing consensus that simple parapneumonic effusions should be treated with drainage and antibiotics, and complicated effusions with either fibrinolysis and chest tube drainage, or early surgical drainage (video-assisted thoracoscopic surgery [VATS]) (<a class="graphic graphic_algorithm graphicRef76277" href="/z/d/graphic/76277.html" rel="external">algorithm 2</a>). (See <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disposition</strong> – The majority of patients with pneumonia complicated by parapneumonic effusions will require hospitalization for further management. Transfer to a facility with specialists in pediatric pulmonology, pediatric surgery, and pediatric anesthesia should be considered early in the care of children with large or loculated effusions because they may require VATS or fibrinolytic therapy. (See <a class="local">'Hospitalization'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotics</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>All children with parapneumonic effusion should be treated with antibiotic therapy. The choice of antibiotic initially is based upon the suspected causative organism, based on characteristics of the patient and local population, and subsequently tailored according to the results of microbiologic testing. (See <a class="local">'Choice of agent'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The duration of antibiotic therapy should be individualized, depending on the adequacy of drainage and clinical response of the patient. A common approach is to continue intravenous (IV) antibiotics for two to five days after resolution of fever, followed by oral therapy to complete a total antibiotic course of two to four weeks. (See <a class="local">'Duration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Free-flowing fluid</strong> – Management of parapneumonic effusion with free-flowing fluid depends on the size of the collection and clinical course of the patient.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Children with small pleural effusions (eg, occupying &lt;1 cm on lateral decubitus radiograph or opacifying less than one-fourth of the hemithorax) who are in no respiratory distress usually can be managed as outpatients, with broad-spectrum oral antibiotics and close observation of clinical symptoms and with chest radiographs (<a class="graphic graphic_algorithm graphicRef78748" href="/z/d/graphic/78748.html" rel="external">algorithm 1</a>). (See <a class="local">'Small parapneumonic effusion'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest that children who present with moderate or large amounts of free fluid documented by chest radiograph and ultrasonography undergo pleural drainage via small-bore chest tube (pigtail catheter) in addition to IV antibiotics, rather than antibiotic therapy alone (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). A 24- to 48-hour trial of antibiotic therapy without chest tube placement is an acceptable alternative for hospitalized, stable patients who are not in respiratory distress and are closely monitored. Patients who respond clinically are continued on antibiotic therapy as described above. (See <a class="local">'Chest tubes'</a> above and <a class="local">'Antibiotic therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chest tube removal is indicated once there is clinical resolution and minimal chest tube drainage. Clinical resolution is indicated by resolution of fever, with decreased white blood cell count, respiratory rate, and heart rate, and improved air entry and sense of well-being. (See <a class="local">'Chest tubes'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who do not have a good clinical and radiologic response within 24 to 48 hours to management with antibiotics with chest tube drainage, we suggest advancing to the therapies used for loculated fluid or empyema (ie, either fibrinolytic therapy or VATS) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). At some institutions, a repeat ultrasound is performed to evaluate for loculation before proceeding to fibrinolytic therapy or VATS. At other institutions, therapy is advanced empirically. (See <a class="local">'Chest tubes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Loculated fluid or empyema</strong> – Patients who have loculated pleural fluid documented by ultrasonography can be treated with either antibiotics alone, pleural catheter placement with fibrinolytics, or surgical therapy (VATS) (<a class="graphic graphic_algorithm graphicRef76277" href="/z/d/graphic/76277.html" rel="external">algorithm 2</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest pleural drainage via small-bore chest tube (pigtail catheter) with fibrinolysis and antibiotics as the initial treatment of choice for children with loculated effusions (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). However, early VATS is an acceptable alternative and may be the first-line option in centers with surgeons experienced with VATS. The choice may be influenced by available expertise, cost considerations, and patient preferences. Pleural drainage with fibrinolysis is successful in approximately 80 percent of children; the remainder who fail medical therapy will require VATS. (See <a class="local">'Intrapleural fibrinolytics versus surgical treatment'</a> above and <a class="local">'Fibrinolytic therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Long-term outcomes are excellent for either primary medical or surgical therapy, but surgical therapy is associated with higher treatment costs and possibly greater short-term complications. (See <a class="local">'Intrapleural fibrinolytics versus surgical treatment'</a> above and <a class="local">'Surgical therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follow-up</strong> – Children who have been treated for parapneumonic effusion should continue to be followed until they have recovered completely. Follow-up chest radiographs are appropriate for patients with residual symptoms or those who had particularly severe disease at presentation. (See <a class="local">'Outpatient follow-up'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Tuomanen EI, Austrian R, Masure HR. Pathogenesis of pneumococcal infection. N Engl J Med 1995; 332:1280.</a></li><li><a class="nounderline abstract_t">Balfour-Lynn IM, Abrahamson E, Cohen G, et al. BTS guidelines for the management of pleural infection in children. Thorax 2005; 60 Suppl 1:i1.</a></li><li><a class="nounderline abstract_t">Jaffé A, Balfour-Lynn IM. Management of empyema in children. Pediatr Pulmonol 2005; 40:148.</a></li><li><a class="nounderline abstract_t">Givan DC, Eigen H. Common pleural effusions in children. Clin Chest Med 1998; 19:363.</a></li><li><a class="nounderline abstract_t">Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011; 53:e25.</a></li><li class="breakAll">Panitch HB, Papastamelos C, Schidlow DV. Abnormalities of the pleural space. In: Pediatric Respiratory Medicine, Taussig LM, Landau LI (Eds), Mosby, St. Louis 1999. p.1184.</li><li><a class="nounderline abstract_t">Alfaro C, Fergie J, Purcell K. Emergence of community-acquired methicillin-resistant Staphylococcus aureus in complicated parapneumonic effusions. Pediatr Infect Dis J 2005; 24:274.</a></li><li><a class="nounderline abstract_t">Mishaan AM, Mason EO Jr, Martinez-Aguilar G, et al. Emergence of a predominant clone of community-acquired Staphylococcus aureus among children in Houston, Texas. Pediatr Infect Dis J 2005; 24:201.</a></li><li><a class="nounderline abstract_t">Hussain FM, Boyle-Vavra S, Bethel CD, Daum RS. Current trends in community-acquired methicillin-resistant Staphylococcus aureus at a tertiary care pediatric facility. Pediatr Infect Dis J 2000; 19:1163.</a></li><li><a class="nounderline abstract_t">Shah SS, Srivastava R, Wu S, et al. Intravenous Versus Oral Antibiotics for Postdischarge Treatment of Complicated Pneumonia. Pediatrics 2016; 138.</a></li><li><a class="nounderline abstract_t">Kushner LE, Nieves DJ, Osborne S, et al. Oral Antibiotics for Treating Children With Community-Acquired Pneumonia Complicated by Empyema. Clin Pediatr (Phila) 2019; 58:1401.</a></li><li><a class="nounderline abstract_t">Stockmann C, Ampofo K, Pavia AT, et al. Comparative Effectiveness of Oral Versus Outpatient Parenteral Antibiotic Therapy for Empyema. Hosp Pediatr 2015; 5:605.</a></li><li><a class="nounderline abstract_t">Svetanoff WJ, Dorman RM, Dekonenko C, et al. Protocol-driven Antibiotic Treatment of Pediatric Empyema After Fibrinolysis. Pediatr Infect Dis J 2021; 40:44.</a></li><li><a class="nounderline abstract_t">Islam S, Calkins CM, Goldin AB, et al. The diagnosis and management of empyema in children: a comprehensive review from the APSA Outcomes and Clinical Trials Committee. J Pediatr Surg 2012; 47:2101.</a></li><li><a class="nounderline abstract_t">Carter E, Waldhausen J, Zhang W, et al. Management of children with empyema: Pleural drainage is not always necessary. Pediatr Pulmonol 2010; 45:475.</a></li><li><a class="nounderline abstract_t">Grewal H, Jackson RJ, Wagner CW, Smith SD. Early video-assisted thoracic surgery in the management of empyema. Pediatrics 1999; 103:e63.</a></li><li><a class="nounderline abstract_t">Rahman NM, Maskell NA, Davies CW, et al. The relationship between chest tube size and clinical outcome in pleural infection. Chest 2010; 137:536.</a></li><li><a class="nounderline abstract_t">Lin CH, Lin WC, Chang JS. Comparison of pigtail catheter with chest tube for drainage of parapneumonic effusion in children. Pediatr Neonatol 2011; 52:337.</a></li><li><a class="nounderline abstract_t">Thomson AH, Hull J, Kumar MR, et al. Randomised trial of intrapleural urokinase in the treatment of childhood empyema. Thorax 2002; 57:343.</a></li><li><a class="nounderline abstract_t">Pierrepoint MJ, Evans A, Morris SJ, et al. Pigtail catheter drain in the treatment of empyema thoracis. Arch Dis Child 2002; 87:331.</a></li><li><a class="nounderline abstract_t">Stavas J, vanSonnenberg E, Casola G, Wittich GR. Percutaneous drainage of infected and noninfected thoracic fluid collections. J Thorac Imaging 1987; 2:80.</a></li><li><a class="nounderline abstract_t">Eibenberger KL, Dock WI, Ammann ME, et al. Quantification of pleural effusions: sonography versus radiography. Radiology 1994; 191:681.</a></li><li><a class="nounderline abstract_t">Maier A, Domej W, Anegg U, et al. Computed tomography or ultrasonically guided pigtail catheter drainage in multiloculated pleural empyema: a recommended procedure? Respirology 2000; 5:119.</a></li><li><a class="nounderline abstract_t">Hunnam GR, Flower CD. Radiologically-guided percutaneous catheter drainage of empyemas. Clin Radiol 1988; 39:121.</a></li><li><a class="nounderline abstract_t">Hyde J, Sykes T, Graham T. Reducing morbidity from chest drains. BMJ 1997; 314:914.</a></li><li><a class="nounderline abstract_t">Laws D, Neville E, Duffy J, Pleural Diseases Group, Standards of Care Committee, British Thoracic Society. BTS guidelines for the insertion of a chest drain. Thorax 2003; 58 Suppl 2:ii53.</a></li><li><a class="nounderline abstract_t">Trapnell DH, Thurston JG. Unilateral pulmonary oedema after pleural aspiration. Lancet 1970; 1:1367.</a></li><li><a class="nounderline abstract_t">Pietsch JB, Whitlock JA, Ford C, Kinney MC. Management of pleural effusions in children with malignant lymphoma. J Pediatr Surg 1999; 34:635.</a></li><li><a class="nounderline abstract_t">Rosen DA, Morris JL, Rosen KR, et al. Analgesia for pediatric thoracostomy tube removal. Anesth Analg 2000; 90:1025.</a></li><li><a class="nounderline abstract_t">Scherer LR, West KW, Weber TR, et al. Staphylococcus epidermidis sepsis in pediatric patients: clinical and therapeutic considerations. J Pediatr Surg 1984; 19:358.</a></li><li class="breakAll">Wheeler JG, Jacobs RF. Pleural effusions and empyema. In: Textbook of Pediatric Infectious Diseases, 6th ed, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders, 2009. p.325.</li><li><a class="nounderline abstract_t">Sonnappa S, Cohen G, Owens CM, et al. Comparison of urokinase and video-assisted thoracoscopic surgery for treatment of childhood empyema. Am J Respir Crit Care Med 2006; 174:221.</a></li><li><a class="nounderline abstract_t">St Peter SD, Tsao K, Spilde TL, et al. Thoracoscopic decortication vs tube thoracostomy with fibrinolysis for empyema in children: a prospective, randomized trial. J Pediatr Surg 2009; 44:106.</a></li><li><a class="nounderline abstract_t">Avansino JR, Goldman B, Sawin RS, Flum DR. Primary operative versus nonoperative therapy for pediatric empyema: a meta-analysis. Pediatrics 2005; 115:1652.</a></li><li><a class="nounderline abstract_t">Tokuda Y, Matsushima D, Stein GH, Miyagi S. Intrapleural fibrinolytic agents for empyema and complicated parapneumonic effusions: a meta-analysis. Chest 2006; 129:783.</a></li><li><a class="nounderline abstract_t">Cameron R, Davies HR. Intra-pleural fibrinolytic therapy versus conservative management in the treatment of adult parapneumonic effusions and empyema. Cochrane Database Syst Rev 2008; :CD002312.</a></li><li><a class="nounderline abstract_t">Hanson SJ, Havens PL, Simpson PM, et al. Intrapleural alteplase decreases parapneumonic effusion volume in children more than saline irrigation. Pediatr Pulmonol 2015; 50:1328.</a></li><li><a class="nounderline abstract_t">Livingston MH, Mahant S, Connolly B, et al. Effectiveness of Intrapleural Tissue Plasminogen Activator and Dornase Alfa vs Tissue Plasminogen Activator Alone in Children with Pleural Empyema: A Randomized Clinical Trial. JAMA Pediatr 2020; 174:332.</a></li><li><a class="nounderline abstract_t">Rahman NM, Maskell NA, West A, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med 2011; 365:518.</a></li><li><a class="nounderline abstract_t">Wells RG, Havens PL. Intrapleural fibrinolysis for parapneumonic effusion and empyema in children. Radiology 2003; 228:370.</a></li><li><a class="nounderline abstract_t">Maskell NA, Davies CW, Nunn AJ, et al. U.K. Controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med 2005; 352:865.</a></li><li><a class="nounderline abstract_t">Hawkins JA, Scaife ES, Hillman ND, Feola GP. Current treatment of pediatric empyema. Semin Thorac Cardiovasc Surg 2004; 16:196.</a></li><li><a class="nounderline abstract_t">Stringel G, Hartman AR. Intrapleural instillation of urokinase in the treatment of loculated pleural effusions in children. J Pediatr Surg 1994; 29:1539.</a></li><li><a class="nounderline abstract_t">Alfageme I, Vázquez R. Ventricular fibrillation after intrapleural urokinase. Intensive Care Med 1997; 23:352.</a></li><li><a class="nounderline abstract_t">Laisaar T, Pullerits T. Effect of intrapleural streptokinase administration on antistreptokinase antibody level in patients with loculated pleural effusions. Chest 2003; 123:432.</a></li><li><a class="nounderline abstract_t">Kercher KW, Attorri RJ, Hoover JD, Morton D Jr. Thoracoscopic decortication as first-line therapy for pediatric parapneumonic empyema. A case series. Chest 2000; 118:24.</a></li><li><a class="nounderline abstract_t">Kern JA, Rodgers BM. Thoracoscopy in the management of empyema in children. J Pediatr Surg 1993; 28:1128.</a></li><li><a class="nounderline abstract_t">Angelillo Mackinlay TA, Lyons GA, Chimondeguy DJ, et al. VATS debridement versus thoracotomy in the treatment of loculated postpneumonia empyema. Ann Thorac Surg 1996; 61:1626.</a></li><li><a class="nounderline abstract_t">Cohen G, Hjortdal V, Ricci M, et al. Primary thoracoscopic treatment of empyema in children. J Thorac Cardiovasc Surg 2003; 125:79.</a></li><li><a class="nounderline abstract_t">Klena JW, Cameron BH, Langer JC, et al. Timing of video-assisted thoracoscopic debridement for pediatric empyema. J Am Coll Surg 1998; 187:404.</a></li><li><a class="nounderline abstract_t">Merry CM, Bufo AJ, Shah RS, et al. Early definitive intervention by thoracoscopy in pediatric empyema. J Pediatr Surg 1999; 34:178.</a></li><li><a class="nounderline abstract_t">Quintero DR, Fan LL. Approach to pleural effusions and empyemas. Paediatr Respir Rev 2004; 5 Suppl A:S151.</a></li><li><a class="nounderline abstract_t">Schultz KD, Fan LL, Pinsky J, et al. The changing face of pleural empyemas in children: epidemiology and management. Pediatrics 2004; 113:1735.</a></li><li><a class="nounderline abstract_t">Gates RL, Caniano DA, Hayes JR, Arca MJ. Does VATS provide optimal treatment of empyema in children? A systematic review. J Pediatr Surg 2004; 39:381.</a></li><li><a class="nounderline abstract_t">Stovroff M, Teague G, Heiss KF, et al. Thoracoscopy in the management of pediatric empyema. J Pediatr Surg 1995; 30:1211.</a></li><li><a class="nounderline abstract_t">Yim AP, Low JM, Ng SK, et al. Video-assisted thoracoscopic surgery in the paediatric population. J Paediatr Child Health 1995; 31:192.</a></li><li><a class="nounderline abstract_t">Doski JJ, Lou D, Hicks BA, et al. Management of parapneumonic collections in infants and children. J Pediatr Surg 2000; 35:265.</a></li><li><a class="nounderline abstract_t">Subramaniam R, Joseph VT, Tan GM, et al. Experience with video-assisted thoracoscopic surgery in the management of complicated pneumonia in children. J Pediatr Surg 2001; 36:316.</a></li><li><a class="nounderline abstract_t">Jaffé A, Cohen G. Thoracic empyema. Arch Dis Child 2003; 88:839.</a></li><li><a class="nounderline abstract_t">Bouros D, Antoniou KM, Chalkiadakis G, et al. The role of video-assisted thoracoscopic surgery in the treatment of parapneumonic empyema after the failure of fibrinolytics. Surg Endosc 2002; 16:151.</a></li><li><a class="nounderline abstract_t">Sit SC, Cohen G, Jaffe A. Urokinase in the treatment of childhood empyema. Thorax 2003; 58:93; author reply 93.</a></li><li><a class="nounderline abstract_t">Kurt BA, Winterhalter KM, Connors RH, et al. Therapy of parapneumonic effusions in children: video-assisted thoracoscopic surgery versus conventional thoracostomy drainage. Pediatrics 2006; 118:e547.</a></li><li><a class="nounderline abstract_t">Mukherjee S, Langroudi B, Rosenthal M, Balfour-Lynn IM. Incidence and outcome of scoliosis in children with pleural infection. Pediatr Pulmonol 2007; 42:221.</a></li><li><a class="nounderline abstract_t">Fraga JC, Kim P. [Surgical treatment of parapneumonic pleural effusion and its complications]. J Pediatr (Rio J) 2002; 78 Suppl 2:S161.</a></li><li><a class="nounderline abstract_t">Tagarro A, Otheo E, Baquero-Artigao F, et al. Dexamethasone for Parapneumonic Pleural Effusion: A Randomized, Double-Blind, Clinical Trial. J Pediatr 2017; 185:117.</a></li><li><a class="nounderline abstract_t">Fitzgerald DB, Waterer GW, Budgeon C, et al. Steroid Therapy and Outcome of Parapneumonic Pleural Effusions (STOPPE): A Pilot Randomized Clinical Trial. Am J Respir Crit Care Med 2022; 205:1093.</a></li><li><a class="nounderline abstract_t">Chan PW, Crawford O, Wallis C, Dinwiddie R. Treatment of pleural empyema. J Paediatr Child Health 2000; 36:375.</a></li><li><a class="nounderline abstract_t">Gocmen A, Kiper N, Toppare M, et al. Conservative treatment of empyema in children. Respiration 1993; 60:182.</a></li><li><a class="nounderline abstract_t">Harris M, Clark J, Coote N, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax 2011; 66 Suppl 2:ii1.</a></li><li><a class="nounderline abstract_t">Satish B, Bunker M, Seddon P. Management of thoracic empyema in childhood: does the pleural thickening matter? Arch Dis Child 2003; 88:918.</a></li><li><a class="nounderline abstract_t">Freij BJ, Kusmiesz H, Nelson JD, McCracken GH Jr. Parapneumonic effusions and empyema in hospitalized children: a retrospective review of 227 cases. Pediatr Infect Dis 1984; 3:578.</a></li><li><a class="nounderline abstract_t">Wise MB, Beaudry PH, Bates DV. Long-term follow-up of staphylococcal pneumonia. Pediatrics 1966; 38:398.</a></li><li><a class="nounderline abstract_t">Hilliard TN, Henderson AJ, Langton Hewer SC. Management of parapneumonic effusion and empyema. Arch Dis Child 2003; 88:915.</a></li><li><a class="nounderline abstract_t">Khakoo GA, Goldstraw P, Hansell DM, Bush A. Surgical treatment of parapneumonic empyema. Pediatr Pulmonol 1996; 22:348.</a></li><li><a class="nounderline abstract_t">Cohen E, Mahant S, Dell SD, et al. The long-term outcomes of pediatric pleural empyema: a prospective study. Arch Pediatr Adolesc Med 2012; 166:999.</a></li><li><a class="nounderline abstract_t">Honkinen M, Lahti E, Svedström E, et al. Long-term recovery after parapneumonic empyema in children. Pediatr Pulmonol 2014; 49:1020.</a></li><li><a class="nounderline abstract_t">Meyerovitch J, Shohet I, Rubinstein E. Analysis of thirty-seven cases of pleural empyema. Eur J Clin Microbiol 1985; 4:337.</a></li><li><a class="nounderline abstract_t">Hoff SJ, Neblett WW, Edwards KM, et al. Parapneumonic empyema in children: decortication hastens recovery in patients with severe pleural infections. Pediatr Infect Dis J 1991; 10:194.</a></li><li><a class="nounderline abstract_t">Redding GJ, Walund L, Walund D, et al. Lung function in children following empyema. Am J Dis Child 1990; 144:1337.</a></li><li><a class="nounderline abstract_t">Kontouli K, Hatziagorou E, Kyrvasilis F, et al. Long-term outcome of parapneumonic effusions in children: Lung function and exercise tolerance. Pediatr Pulmonol 2015; 50:615.</a></li><li><a class="nounderline abstract_t">de Benedictis FM, Carloni I, Osimani P, et al. Prospective evaluation of lung function in children with parapneumonic empyema. Pediatr Pulmonol 2019; 54:421.</a></li></ol></div><div id="topicVersionRevision">Topic 6345 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7708073" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pathogenesis of pneumococcal infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15681514" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : BTS guidelines for the management of pleural infection in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15965900" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Management of empyema in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9646987" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Common pleural effusions in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21880587" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21880587" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15750470" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Emergence of community-acquired methicillin-resistant Staphylococcus aureus in complicated parapneumonic effusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15750454" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Emergence of a predominant clone of community-acquired Staphylococcus aureus among children in Houston, Texas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11144377" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Current trends in community-acquired methicillin-resistant Staphylococcus aureus at a tertiary care pediatric facility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27940695" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Intravenous Versus Oral Antibiotics for Postdischarge Treatment of Complicated Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31122051" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Oral Antibiotics for Treating Children With Community-Acquired Pneumonia Complicated by Empyema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26526596" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Comparative Effectiveness of Oral Versus Outpatient Parenteral Antibiotic Therapy for Empyema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32852350" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Protocol-driven Antibiotic Treatment of Pediatric Empyema After Fibrinolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23164006" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The diagnosis and management of empyema in children: a comprehensive review from the APSA Outcomes and Clinical Trials Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20425855" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Management of children with empyema: Pleural drainage is not always necessary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10224207" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Early video-assisted thoracic surgery in the management of empyema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19820073" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The relationship between chest tube size and clinical outcome in pleural infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22192262" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Comparison of pigtail catheter with chest tube for drainage of parapneumonic effusion in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11923554" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Randomised trial of intrapleural urokinase in the treatment of childhood empyema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12244011" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pigtail catheter drain in the treatment of empyema thoracis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3302292" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Percutaneous drainage of infected and noninfected thoracic fluid collections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8184046" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Quantification of pleural effusions: sonography versus radiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10894100" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Computed tomography or ultrasonically guided pigtail catheter drainage in multiloculated pleural empyema: a recommended procedure?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3281777" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Radiologically-guided percutaneous catheter drainage of empyemas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9099109" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Reducing morbidity from chest drains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12728150" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : BTS guidelines for the insertion of a chest drain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4194125" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Unilateral pulmonary oedema after pleural aspiration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10235342" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Management of pleural effusions in children with malignant lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10781447" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Analgesia for pediatric thoracostomy tube removal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6481577" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Staphylococcus epidermidis sepsis in pediatric patients: clinical and therapeutic considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6481577" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Staphylococcus epidermidis sepsis in pediatric patients: clinical and therapeutic considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16675783" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Comparison of urokinase and video-assisted thoracoscopic surgery for treatment of childhood empyema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19159726" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Thoracoscopic decortication vs tube thoracostomy with fibrinolysis for empyema in children: a prospective, randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15930229" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Primary operative versus nonoperative therapy for pediatric empyema: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16537882" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Intrapleural fibrinolytic agents for empyema and complicated parapneumonic effusions: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18425881" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Intra-pleural fibrinolytic therapy versus conservative management in the treatment of adult parapneumonic effusions and empyema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25847131" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Intrapleural alteplase decreases parapneumonic effusion volume in children more than saline irrigation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32011642" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Effectiveness of Intrapleural Tissue Plasminogen Activator and Dornase Alfa vs Tissue Plasminogen Activator Alone in Children with Pleural Empyema: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21830966" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Intrapleural use of tissue plasminogen activator and DNase in pleural infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12893898" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Intrapleural fibrinolysis for parapneumonic effusion and empyema in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15745977" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : U.K. Controlled trial of intrapleural streptokinase for pleural infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15619185" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Current treatment of pediatric empyema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7877021" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Intrapleural instillation of urokinase in the treatment of loculated pleural effusions in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9083243" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Ventricular fibrillation after intrapleural urokinase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12576362" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Effect of intrapleural streptokinase administration on antistreptokinase antibody level in patients with loculated pleural effusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10893354" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Thoracoscopic decortication as first-line therapy for pediatric parapneumonic empyema. A case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8308676" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Thoracoscopy in the management of empyema in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8651759" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : VATS debridement versus thoracotomy in the treatment of loculated postpneumonia empyema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12538988" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Primary thoracoscopic treatment of empyema in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9783787" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Timing of video-assisted thoracoscopic debridement for pediatric empyema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10022167" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Early definitive intervention by thoracoscopy in pediatric empyema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14980262" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Approach to pleural effusions and empyemas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15173499" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The changing face of pleural empyemas in children: epidemiology and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15017556" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Does VATS provide optimal treatment of empyema in children? A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7472986" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Thoracoscopy in the management of pediatric empyema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7669378" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Video-assisted thoracoscopic surgery in the paediatric population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10693678" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Management of parapneumonic collections in infants and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11172424" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Experience with video-assisted thoracoscopic surgery in the management of complicated pneumonia in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14500294" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Thoracic empyema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11961627" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The role of video-assisted thoracoscopic surgery in the treatment of parapneumonic empyema after the failure of fibrinolytics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12511733" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Urokinase in the treatment of childhood empyema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16908618" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Therapy of parapneumonic effusions in children: video-assisted thoracoscopic surgery versus conventional thoracostomy drainage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17238191" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Incidence and outcome of scoliosis in children with pleural infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14676855" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : [Surgical treatment of parapneumonic pleural effusion and its complications].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28363363" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Dexamethasone for Parapneumonic Pleural Effusion: A Randomized, Double-Blind, Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35081010" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Steroid Therapy and Outcome of Parapneumonic Pleural Effusions (STOPPE): A Pilot Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10940174" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Treatment of pleural empyema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8210723" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Conservative treatment of empyema in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21903691" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14500315" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Management of thoracic empyema in childhood: does the pleural thickening matter?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6514596" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Parapneumonic effusions and empyema in hospitalized children: a retrospective review of 227 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5918388" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Long-term follow-up of staphylococcal pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14500314" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Management of parapneumonic effusion and empyema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9016468" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Surgical treatment of parapneumonic empyema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22945017" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The long-term outcomes of pediatric pleural empyema: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24339218" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Long-term recovery after parapneumonic empyema in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3926490" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Analysis of thirty-seven cases of pleural empyema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2041665" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Parapneumonic empyema in children: decortication hastens recovery in patients with severe pleural infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2244616" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Lung function in children following empyema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24777950" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Long-term outcome of parapneumonic effusions in children: Lung function and exercise tolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30589234" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Prospective evaluation of lung function in children with parapneumonic empyema.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
